Opinion|Videos|March 13, 2026

Resistance mechanisms in EGFR-Mutated NSCLC

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss resistance mechanisms in EGFR-mutated NSCLC.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, review both on-target and off-target resistance mechanisms that emerge during EGFR-directed therapy in EGFR-mutated NSCLC. Vokes explains how secondary EGFR mutations, MET amplification, and histologic transformation contribute to therapeutic failure. Devarakonda discusses the clinical importance of comprehensive molecular profiling to guide subsequent treatment selection.


Latest CME